/
Biological products, (no diagnostic substances) company · DE · FY ends Apr · Revenue $58M · -4.53% margin · $4M FCF
Operating margin is thin at 8.00%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 13.5% YoY with margins expanding 22.7pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$58M
▲ +13.5% YoY
Net Income (TTM)
-$2M
▲ +164.6% YoY
Op. Margin
-4.53%
▲ +22.7pp YoY
ROIC
-21.60%
▲ +105.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▲ +200.3% YoY
Op. Cash Flow (TTM)
$4M
▲ +220.4% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$7M
5Y CAGR: +12.1%
5Y CAGR: +59.2%
Continue Research